BC Extra | Nov 28, 2018
Preclinical News

Placental organoid could improve preeclampsia therapies

A placenta-like organoid developed by a University of Cambridge team could improve understanding of maternal-fetal first-trimester disorders like preeclampsia and provide a model to study therapies to treat first-trimester complications. Challenges in preeclampsia and other...
BC Week In Review | Jun 9, 2017
Clinical News

Velo begins Phase IIb/III for digoxin immune fab to treat severe preeclampsia

AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) said Velo Bio LLC (Morrisville, N.C.) began a double-blind, U.S. Phase IIb/IIIa trial to evaluate digoxin immune fab (DIF, DigiFab) in about 200 antepartum women with severe preeclampsia. AMAG has an...
BC Innovations | Jun 23, 2016
Tools & Techniques

Home is in the placenta

Many drug developers have avoided stepping into what they see as the high risk area of pregnancy-associated complications, leaving diseases such as preeclampsia and fetal growth restriction with little innovation and few treatment options. By...
BC Innovations | Apr 21, 2016
Product R&D

A1M for preeclampsia

A poor understanding of disease biology and a challenging development pathway have kept most drug developers away from the serious pregnancy complication preeclampsia, but A1M Pharma AB has a new approach with a first-in-class therapy...
BC Week In Review | Dec 3, 2012
Clinical News

Digibind digoxin immune fab regulatory update

FDA granted Fast Track designation for Glenveigh's digoxin immune fab to treat severe preeclampsia. The polyclonal antibody fragment that neutralizes digoxin is clinical testing to treat eclampsia and preeclampsia. Glenveigh could not be reached for...
BC Week In Review | Feb 20, 2012
Clinical News

Digibind digoxin immune fab regulatory update

FDA granted Orphan Drug designation for Glenveigh's Digibind to treat severe preeclampsia and eclampsia. The polyclonal antibody fragment that neutralizes digoxin is already approved to treat digoxin toxicity. Glenveigh Medical LLC , Chattanooga, Tenn.   Product:...
BC Week In Review | Apr 28, 2008
Clinical News

Digibind: Phase IIb data

In the Phase IIb DEEP trial in 51 pregnant women with severe preeclampsia for whom baby delivery was necessary within 72 hours, Digibind met 1 of the 2 primary endpoints. The compound significantly improved creatinine...
BioCentury | Apr 28, 2008
Finance

Ebb & Flow

On Friday, investors savaged Isis (NASDAQ:ISIS) and dinged partner Genzyme (NASDAQ:GENZ) on news that NDA submissions for their mipomersen cholesterol-lowering drug would take longer than anticipated. Isis fell $4.81 (29%) to $11.99, while Genzyme dipped...
BC Extra | Apr 23, 2008
Clinical News

Protherics reports Digibind data

Protherics (LSE:PTI; NASDAQ:PTIL) said Digibind met one of the two primary endpoints in the Phase IIb DEEP trial in 51 pregnant women with severe preeclampsia for whom baby delivery was necessary within 72 hours. The...
BC Week In Review | Dec 3, 2007
Clinical News

Digibind: Completed Phase IIb enrollment

PTI completed enrollment of 50 females in their 24-34th week of pregnancy in the placebo-controlled Phase IIb DEEP trial. The company licensed rights to Digibind from Glenveigh last year (see BioCentury, Dec. 11, 2006). Glenveigh...
Items per page:
1 - 10 of 14